Reckitt Benckiser Group, which used to own Suboxone maker Indivior, has agreed to pay $700 million to the federal government and $50 million to settle Federal Trade Commissioner charges that the company violated antitrust laws in an attempt to thwart generic competition to the opioid addiction treatment drug Suboxone.